Impact of Karnofsky performance status on outcomes of patients with severe alcohol-associated hepatitis: a propensity-matched analysis.

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Anand V Kulkarni, Shantan Venishetty, Karan Kumar, Nitish Gurav, Somaya Albhaisi, Prateek Chhabbra, Sameer Shaik, Manasa Alla, Sowmya Iyengar, Mithun Sharma, Padaki N Rao, Juan P Arab, Duvvur N Reddy
{"title":"Impact of Karnofsky performance status on outcomes of patients with severe alcohol-associated hepatitis: a propensity-matched analysis.","authors":"Anand V Kulkarni, Shantan Venishetty, Karan Kumar, Nitish Gurav, Somaya Albhaisi, Prateek Chhabbra, Sameer Shaik, Manasa Alla, Sowmya Iyengar, Mithun Sharma, Padaki N Rao, Juan P Arab, Duvvur N Reddy","doi":"10.1111/imj.16562","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Severity scores, including the model for end-stage liver disease (MELD) and discriminant function score, guide the treatment of patients with severe alcohol-associated hepatitis (AH). We aimed to investigate the impact of functional status on outcomes of patients with AH.</p><p><strong>Methods: </strong>Medically managed patients (n = 133) with AH from 1 January 2019 to 31 December 2022 were included in this prospective study. The objectives were to compare the long-term survival, recompensation rates, corticosteroid response, incidence of infections, hepatic encephalopathy (HE) and acute kidney injury (AKI) among propensity score-matched patients with good Karnofsky performance status (KPS) (score ≥50) and poor KPS (score <50) using Kaplan-Meier analysis.</p><p><strong>Results: </strong>Twenty-five patients with good KPS were matched with 25 patients with poor KPS and followed up for a median duration of 10 (0.5-33) months. Survival was 76% (19/25; 95% confidence interval (CI), 54.9-90.6) in patients with good KPS compared to 42.3% (11/25; 95% CI, 23.4-63.1) patients with poor KPS (P = 0.001) at 10 months. The recompensation rate was higher in the good KPS group than in the poor KPS group (68% vs 44%; P = 0.04). A higher proportion of patients in the good KPS group (78.9%) than in the poor KPS group (42.8%; P = 0.03) responded to corticosteroids. Survival was lower among non-responders in the poor KPS group (0% vs 75%; P = 0.01). The proportion of patients who developed infection (36% vs 28%; P = 0.051), HE (36% vs 12%; P = 0.01) and AKI (60% vs 16%; P < 0.001) was higher in patients with poor KPS than in good KPS.</p><p><strong>Conclusions: </strong>KPS is an important determinant of outcomes in patients with AH, including survival, recompensation, response to corticosteroids and complications.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.16562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: Severity scores, including the model for end-stage liver disease (MELD) and discriminant function score, guide the treatment of patients with severe alcohol-associated hepatitis (AH). We aimed to investigate the impact of functional status on outcomes of patients with AH.

Methods: Medically managed patients (n = 133) with AH from 1 January 2019 to 31 December 2022 were included in this prospective study. The objectives were to compare the long-term survival, recompensation rates, corticosteroid response, incidence of infections, hepatic encephalopathy (HE) and acute kidney injury (AKI) among propensity score-matched patients with good Karnofsky performance status (KPS) (score ≥50) and poor KPS (score <50) using Kaplan-Meier analysis.

Results: Twenty-five patients with good KPS were matched with 25 patients with poor KPS and followed up for a median duration of 10 (0.5-33) months. Survival was 76% (19/25; 95% confidence interval (CI), 54.9-90.6) in patients with good KPS compared to 42.3% (11/25; 95% CI, 23.4-63.1) patients with poor KPS (P = 0.001) at 10 months. The recompensation rate was higher in the good KPS group than in the poor KPS group (68% vs 44%; P = 0.04). A higher proportion of patients in the good KPS group (78.9%) than in the poor KPS group (42.8%; P = 0.03) responded to corticosteroids. Survival was lower among non-responders in the poor KPS group (0% vs 75%; P = 0.01). The proportion of patients who developed infection (36% vs 28%; P = 0.051), HE (36% vs 12%; P = 0.01) and AKI (60% vs 16%; P < 0.001) was higher in patients with poor KPS than in good KPS.

Conclusions: KPS is an important determinant of outcomes in patients with AH, including survival, recompensation, response to corticosteroids and complications.

卡诺夫斯基表现状态对重症酒精相关性肝炎患者预后的影响:倾向匹配分析。
背景和目的:严重程度评分,包括终末期肝病模型(MELD)和判别功能评分,是治疗严重酒精相关性肝炎(AH)患者的指导原则。我们旨在研究功能状态对酒精相关性肝炎患者预后的影响:这项前瞻性研究纳入了 2019 年 1 月 1 日至 2022 年 12 月 31 日期间接受药物治疗的酒精相关性肝炎患者(n = 133)。目的:比较卡诺夫斯基表现状态(KPS)良好(评分≥50)和KPS较差(评分≥50)患者的长期生存率、恢复率、皮质类固醇反应、感染、肝性脑病(HE)和急性肾损伤(AKI)的发生率:25 名 KPS 良好的患者与 25 名 KPS 较差的患者进行了匹配,随访时间中位数为 10(0.5-33)个月。10 个月时,KPS 良好患者的存活率为 76%(19/25;95% 置信区间 (CI),54.9-90.6),而 KPS 较差患者的存活率为 42.3%(11/25;95% 置信区间 (CI),23.4-63.1)(P = 0.001)。KPS良好组的再补偿率高于KPS不良组(68% vs 44%; P = 0.04)。对皮质类固醇有反应的 KPS 良好组患者比例(78.9%)高于 KPS 较差组(42.8%;P = 0.03)。KPS 较差组中无应答者的存活率较低(0% vs 75%;P = 0.01)。发生感染(36% 对 28%;P = 0.051)、高血压(36% 对 12%;P = 0.01)和急性肾功能衰竭(60% 对 16%;P 结论:KPS 是决定患者病情的重要因素:KPS 是决定 AH 患者预后的重要因素,包括存活率、恢复情况、对皮质类固醇的反应和并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信